Presentation is loading. Please wait.

Presentation is loading. Please wait.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Published byManuela Sánchez Carmona Modified over 6 years ago

Similar presentations

Presentation on theme: "A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki."— Presentation transcript:

1 A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki Drogari, MD, PhD, MSc (Biochem), MSc (Nutr)  Journal of Clinical Lipidology  Volume 10, Issue 5, Pages e3 (September 2016) DOI: /j.jacl Copyright © 2016 National Lipid Association Terms and Conditions

2 Figure 1 Patient disposition. AE, adverse event; LDL-C, low-density lipoprotein cholesterol; TS, Tanner stage. *LDL-C <2.59 mmol/L (100 mg/dL). Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

3 Figure 2 (A) Mean unweighted, weighted, and maximum doses of atorvastatin received by children and adolescents with HeFH stratified by TS and age. (B) The percentage of subjects receiving atorvastatin 5, 10, 20, 40, or 80 mg as their maximum dose, all subjects, by TS and age. HeFH, heterozygous familial hypercholesterolemia; SE, standard error; TS, Tanner stage. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

4 Figure 3 Mean percentage change from baseline in LDL-C in all subjects with HeFH and by TS 1 and ≥2 and aged <10 and ≥10 years at baseline. HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; TS, Tanner stage. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

5 Figure 4 Percentage of subjects aged <10 years or ≥10 years at baseline achieving LDL-C goal of <3.35 mmol/L (<130 mg/dL) at each study visit. LDL-C, low-density lipoprotein cholesterol. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

6 Figure 5 Mean percentage change from baseline in lipid parameters at month 36/early termination in all subjects with HeFH and by TS 1 and ≥2 at baseline. Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; TC, total cholesterol; TG, triglyceride; TS, Tanner stage. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

7 Figure 6 Changes in the percentage of subjects in each TS over 36 months/early termination among children and adolescents with HeFH receiving atorvastatin therapy. HeFH, heterozygous familial hypercholesterolemia; TS, Tanner stage. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

8 Supplemental Figure 1 Mean FMD in a subset of subjects over 36 months among children and adolescents with HeFH receiving atorvastatin therapy. FMD, flow-mediated dilation; HeFH, heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology  , e3DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

Download ppt "A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki."

Similar presentations

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
My Approach to the Patient With Familial Hypercholesterolemia

My Approach to the Patient With Familial Hypercholesterolemia
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,
A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Similar presentations

Ads by Google